Telaprevir
- Generic Name
- Telaprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H53N7O6
- CAS Number
- 402957-28-2
- Unique Ingredient Identifier
- 655M5O3W0U
- Background
Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...
- Indication
Telaprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults .
- Associated Conditions
- Chronic Hepatitis C Genotype 1
- Associated Therapies
- -
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Valme University Hospital
- Target Recruit Count
- 1128
- Registration Number
- NCT02333292
- Locations
- 🇪🇸
Valme University Hospital, Seville, Andalusia, Spain
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
- Conditions
- Interventions
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Louis Stokes VA Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT02113631
- Locations
- 🇺🇸
Louis Stokes Cleveland VA medical center, Cleveland, Ohio, United States
Telaprevir in Genotype 3 HCV
- Conditions
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 14
- Registration Number
- NCT02087111
- Locations
- 🇬🇧
Nottingham University Hospitals Trust, Nottingham, United Kingdom
🇬🇧Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom
🇬🇧Ste Georges Healthcare NHS Trust, London, United Kingdom
Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 20
- Registration Number
- NCT02006745
- Locations
- 🇬🇧
St Stephens AIDS Trust, London, United Kingdom
Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Timothy Morgan, MD
- Registration Number
- NCT01890772
- Locations
- 🇺🇸
Minneapolis VAHCS, Minneapolis, Minnesota, United States
🇺🇸VA Long Beach Healthcare System, Long Beach, California, United States
🇺🇸Kansas City VA Medical Center, Kansas City, Missouri, United States
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Santaris Pharma A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01872936
- Locations
- 🇺🇸
Research Specialists of Texas, Houston, Texas, United States
🇺🇸The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States
🇵🇷Fundacion de Investigacion de Diego, San Juan, Puerto Rico
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
- Conditions
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01858961
- Locations
- 🇦🇺
1241.37.61002 Boehringer Ingelheim Investigational Site, Westmead, New South Wales, Australia
🇸🇪1241.37.46001 Boehringer Ingelheim Investigational Site, Stockholm, Sweden
🇪🇸1241.37.34003 Boehringer Ingelheim Investigational Site, Madrid, Spain
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 148
- Registration Number
- NCT01854528
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 311
- Registration Number
- NCT01854697
Interaction Between Paroxetine and Telaprevir
- Conditions
- Interventions
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT01841502
- Locations
- 🇳🇱
Academic Medical Centre Amsterdam, Amsterdam, Netherlands
🇳🇱Reinier de Graaf Groep, Delft, Netherlands
🇳🇱University Medical Centre Groningen, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.